评估新型商业化干扰素-γ释放试验对结核分枝杆菌感染的诊断性能:系统综述与Meta分析
该系统综述与Meta分析纳入87项研究,比较6种新型干扰素-γ释放试验(IGRA)与WHO认可的IGRA对结核感染的诊断性能。与QFT-GIT相比,QFT-Plus的敏感性低0.1个百分点(95%CI -2.8至2.6),特异性低0.9个百分点(95%CI -1.0至-0.9);TB-IGRA的敏感性高3.0个百分点(95%CI -0.2至6.2),特异性低2.6个百分点(95%CI -4.2至-1.0)。QFT-Plus CLIA和QIAreach与QFT-Plus的一致性极好(κ分别为0.86和0.96),TB-Feron与QFT-Plus或QFT-GIT的κ为0.85。结论认为QFT-Plus和TB-IGRA与WHO批准的IGRA敏感性和特异性非常相似。
要点
- QFT-Plus与QFT-GIT敏感性低0.1个百分点,特异性低0.9个百分点(证据确定性中等)。
- TB-IGRA与QFT-GIT敏感性高3.0个百分点,特异性低2.6个百分点(证据确定性极低/低)。
- QFT-Plus CLIA和QIAreach与QFT-Plus一致性极好,κ分别为0.86和0.96。
核心结论
- QFT-Plus和TB-IGRA与WHO批准的IGRA具有非常相似的敏感性和特异性。
研究设计与样本
- 系统综述与Meta分析,检索2007年1月1日至2021年8月18日的Medline、Embase、Web of Science、Cochrane系统综述数据库及制造商数据。
- 纳入比较索引试验与参考试验诊断性能的横断面和队列研究,共87项研究。
- 44项评估QFT-Plus,4项评估QFT-Plus CLIA,3项评估QIAreach,26项评估TB-IGRA,10项评估TB-Feron(其中1项同时评估QFT-Plus),1项评估T-SPOT.TB/T-Cell Select。
主要发现
- 与QFT-GIT相比,QFT-Plus的敏感性低0.1个百分点(95%CI -2.8至2.6;证据确定性中等),特异性低0.9个百分点(95%CI -1.0至-0.9;证据确定性中等)。
- 与QFT-GIT相比,TB-IGRA的敏感性高3.0个百分点(95%CI -0.2至6.2;证据确定性极低),特异性低2.6个百分点(95%CI -4.2至-1.0;证据确定性低)。
- QFT-Plus CLIA与QFT-Plus的合并κ统计量为0.86(95%CI 0.78至0.94;证据确定性低),QIAreach与QFT-Plus的合并κ为0.96(95%CI 0.92至1.00;证据确定性低)。
- TB-Feron与QFT-Plus或QFT-GIT比较的合并κ统计量为0.85(95%CI 0.79至0.92;证据确定性低)。
关键数值与推荐
- 敏感性差异:QFT-Plus较QFT-GIT低0.1个百分点(95%CI -2.8至2.6)。
- 特异性差异:QFT-Plus较QFT-GIT低0.9个百分点(95%CI -1.0至-0.9)。
- 敏感性差异:TB-IGRA较QFT-GIT高3.0个百分点(95%CI -0.2至6.2)。
- 特异性差异:TB-IGRA较QFT-GIT低2.6个百分点(95%CI -4.2至-1.0)。
- 一致性:QFT-Plus CLIA与QFT-Plus的κ为0.86(95%CI 0.78至0.94);QIAreach与QFT-Plus的κ为0.96(95%CI 0.92至1.00);TB-Feron与QFT-Plus或QFT-GIT的κ为0.85(95%CI 0.79至0.92)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We compared 6 new interferon-γ release assays (IGRAs; hereafter index tests: QFT-Plus, QFT-Plus CLIA, QIAreach, Wantai TB-IGRA, Standard E TB-Feron, and T-SPOT.TB/T-Cell Select) with World Health Organization (WHO)-endorsed tests for tuberculosis infection (hereafter reference tests). METHODS: Data sources (1 January 2007-18 August 2021) were Medline, Embase, Web of Science, Cochrane Database of Systematic Reviews, and manufacturers' data. Cross-sectional and cohort studies comparing the diagnostic performance of index and reference tests were selected. The primary outcomes of interest were the pooled differences in sensitivity and specificity between index and reference tests. The certainty of evidence (CoE) was summarized using the GRADE approach. RESULTS: Eighty-seven studies were included (44 evaluated the QFT-Plus, 4 QFT-Plus CLIA, 3 QIAreach, 26 TB-IGRA, 10 TB-Feron [1 assessing the QFT-Plus], and 1 T-SPOT.TB/T-Cell Select). Compared to the QFT-GIT, QFT Plus's sensitivity was 0.1 percentage points lower (95% confidence interval [CI], -2.8 to 2.6; CoE: moderate), and its specificity 0.9 percentage points lower (95% CI, -1.0 to -.9; CoE: moderate). Compared to QFT-GIT, TB-IGRA's sensitivity was 3.0 percentage points higher (95% CI, -.2 to 6.2; CoE: very low), and its specificity 2.6 percentage points lower (95% CI, -4.2 to -1.0; CoE: low). Agreement between the QFT-Plus CLIA and QIAreach with QFT-Plus was excellent (pooled κ statistics of 0.86 [95% CI, .78 to .94; CoE: low]; and 0.96 [95% CI, .92 to 1.00; CoE: low], respectively). The pooled κ statistic comparing the TB-Feron and the QFT-Plus or QFT-GIT was 0.85 (95% CI, .79 to .92; CoE: low). CONCLUSIONS: The QFT-Plus and the TB-IGRA have very similar sensitivity and specificity as WHO-approved IGRAs.
引用
- Ortiz-Brizuela E, Apriani L, Mukherjee T, et al. Assessing the Diagnostic Performance of New Commercial Interferon-γ Release Assays for Mycobacterium tuberculosis Infection: A Systematic Review and Meta-Analysis. Clin Infect Dis. 2023. PMID: 36688489. doi:10.1093/cid/ciad030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。